Gastrointestinal Cancers

Dr. McKenzie explains bile duct cancer subtypes, genomic profiling, targeted therapies and multidisciplinary strategies to improve quality of life.

Dr. McKenzie discusses gallbladder cancer risk factors, imaging signs and how surgery and lymph node evaluation impact outcomes.

The U.S. FDA has granted orphan drug designation to HCB101, an investigational immunotherapy, for the treatment of gastric cancer.

The FDA has granted orphan drug designation to zenocutuzumab-zbco for the treatment of adults with advanced unresectable or metastatic cholangiocarcinoma.

Dr. Suneel Kamath walks patients through what they need to know about their gastrointestinal cancers following major oncology meetings.

Dr. Suneel Kamath highlighted advances in biomarker-driven therapies and emerging frontline regimens following the 2026 ASCO GI Cancers Symposium.

Experts highlight key themes from the ASCO GI Cancers Symposium, including the growing role of AI and an increased emphasis on patient-centered decision-making.

Patient education and individualized navigation can improve genomic testing uptake and downstream participation in genomics-based clinical trials.

Patients with advanced gastric cancer received PD-1 inhibitors at similar rates across racial groups, although overall use remained limited in real-world care.

Providing patient-centered education and navigation support significantly increases consent rates for genomic testing, making testing integration feasible.

Nutritional support helps malnourished patients with advanced gastric cancer maintain chemotherapy and may extend time to treatment failure.

Updated data from GOBLET Cohort 4 demonstrated activity with Reolysin plus Tecentriq in patients with third-line metastatic squamous cell anal carcinoma.

Understanding your diagnosis, the tests ahead and the treatment landscape is the first step in regaining a sense of control.

ECOG performance status was found to capture only part of the patient experience in gastric/GEJ adenocarcinoma.

These were the top gastrointestinal cancer stories published by CURE in 2025.

Dr. William A. Hall discusses overtreatment in gastrointestinal cancer care and how AI-driven response assessment is shaping personalized treatment.

Education is a vital step in navigating gallbladder cancer care.

An expert discusses how precision oncology, immunotherapy, biomarker testing and clinical trials are expanding treatment options for patients with gastric cancer.

I share how an overlooked symptom led to my anal cancer diagnosis and why speaking openly about risks, stigma and symptoms can help others seek care sooner.

A diagnosis of anal cancer can feel overwhelming, but understanding the disease is the first step toward effective management and recovery.

Gastric cancer care highlights eating difficulties, weight loss and side effects showing why nutrition support and clinical trials are key

Cindy and Katie share how finding a friend who understood the caregiving journey made the experience less isolating and helped them navigate loss and hope.

The oral therapy DPTX3186 received fast track status to help speed development of a potential new option for patients with gastric cancer.

These are the basics of bile duct cancer, from diagnosis to treatment.

Long-awaited progress in rectal and gastric cancer research includes a fast track designation and new survival data.